Insider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells $19,899.00 in Stock

Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Jeetinder Singh Mahal sold 900 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $22.11, for a total transaction of $19,899.00. Following the sale, the chief operating officer now owns 25,009 shares in the company, valued at approximately $552,948.99. This trade represents a 3.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jasper Therapeutics Trading Up 0.6 %

JSPR stock opened at $20.60 on Friday. The firm’s 50-day moving average price is $21.00 and its two-hundred day moving average price is $20.84. Jasper Therapeutics, Inc. has a 12-month low of $4.24 and a 12-month high of $31.01. The stock has a market capitalization of $309.02 million, a price-to-earnings ratio of -4.35 and a beta of 2.18.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds have recently modified their holdings of the company. Barclays PLC increased its position in shares of Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the period. Jane Street Group LLC purchased a new position in shares of Jasper Therapeutics during the third quarter valued at about $251,000. Wellington Management Group LLP purchased a new position in shares of Jasper Therapeutics during the third quarter valued at about $447,000. State Street Corp increased its position in shares of Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after buying an additional 23,564 shares during the period. Finally, Samsara BioCapital LLC increased its position in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after buying an additional 59,642 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Analyst Ratings Changes

JSPR has been the topic of several research reports. Evercore ISI restated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and an average price target of $73.38.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.